A novel ritonavir oral powder formulation has been developed to eliminate the alcohol and propylene glycol contents in the current ritonavir oral solution for paediatric use. Two clinical studies were conducted to assess the bioequivalence of the powder formulation to the marketed oral solution and to evaluate the effect of food and vehicles on bioavailability.
Methods
Study 1 was a randomized, partial-crossover, 4-period study in 48 subjects. Regimens included: oral solution under moderate-fat conditions, powder formulation in water under fasting, moderate-fat or high-fat conditions, and powder formulation in chocolate milk or pudding under moderate-fat conditions. Study 2 was a randomized, crossover, 4-period study in 24 subjects. Subjects were randomized to a sequence of the oral solution and powder formulation in water, infant formula and apple sauce, all under moderate-fat conditions. Bioavailability comparisons were assessed by the 90% CIs for the geometric least-squares mean ratios.
Results
Ritonavir powder formulation in water was found to be bioequivalent to the marketed oral solution. Ritonavir powder formulation administered in chocolate milk, pudding, infant formula or apple sauce was bio-equivalent to the powder formulation administered in water. Compared with fasting conditions, moderate-fat and high-fat meals were associated with approximately 25–40% and 35–50% reduction in ritonavir concentrations, respectively.
Conclusions
The novel ritonavir powder formulation is bioequivalent to marketed ritonavir oral solution under moderate-fat conditions with a similar effect of meals. None of the vehicles tested negatively affected the bioavailability, which suggests the potential for use of a broad range of vehicles for dose preparation.
References
1.
HullM.W., MontanerJ.S.Ritonavir-boosted protease inhibitors in HIV therapy.Ann Med2011; 43: 375–388.
2.
MyaseinF., KimE., ZhangJ., WuH., El-ShourbagyT.A.Rapid, simultaneous determination of lopinavir and ritonavir in human plasma by stacking protein precipitations and salting-out assisted liquid/liquid extraction, and ultrafast LC–MS/MS.Anal Chim Acta2009; 651: 112–116.
3.
KleinC., ChiuY., AwniW.The effect of food on ritonavir bioavailability following administration of ritonavir 100 mg film-coated tablet in healthy adult subjects.Seventh International Congress on Drug Therapy in HIV Infection. 9–13 November 2008, Glasgow, Scotland. Abstract P247.
4.
Norvir (ritonavir).Package insert2013. AbbVie Inc.North Chicago, IL, USA.
5.
Reyataz (atazanavir).Package insert2014. Bristol–Myers SquibbPrinceton, NJ, USA.
6.
Prezista (darunavir).Package insert2014. Janssen TherapeuticsTitusville, NJ, USA.
7.
ShiauY.F., FernandezP., JacksonM.J., McMonagleS.Mechanisms maintaining a low-pH microclimate in the intestine.Am J Physiol1985; 248: G608–G617.
8.
CharmanW.N., PorterC.J., MithaniS., DressmanJ.B.Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH.J Pharm Sci1997; 86: 269–282.
9.
MarasanapalleV.P., CrisonJ.R., MaJ., LiX., JastiB.R.Investigation of some factors contributing to negative food effects.Biopharm Drug Dispos2009; 30: 71–80.
10.
KleinC.E., ChiuY.L., CaiY.Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.J Clin Pharmacol2008; 48: 553–562.
11.
SekarV.J., LefebvreE., De PaepeE.Pharmacokinetic interaction between darunavir boosted with ritonavir and omeprazole or ranitidine in human immunodeficiency virus-negative healthy volunteers.Antimicrob Agents Chemother2007; 51: 958–961.
